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It isknownthatmonogenic traitsmaypredisposeyoungandotherwisehealthy individuals to
die suddenly. Diseases such as Long QT Syndrome, Brugada Syndrome and Arrhythmogenic
Right Ventricular Cardiomyopathy are well known causes of arrhythmic death in young in-
dividuals. For several years the concept of “genetic predisposition” to sudden cardiac death
has been limited to these uncommon diseases. In the last few years clinical data have sup-
ported theviewthat riskofdyingsuddenlymaycluster in families, supporting thehypothesis
of a genetic component for sudden cardiac death. In this review I will try to provide an
overview of current knowledge about genetics of sudden death. I will approach this topic by
discussing first where we stand in the use of genetics for risk stratification and therapy se-
lection inmonogenic diseases and I will thenmove to discuss the contribution of genetics to
patient profiling in acquired cardiovascular diseases.
Copyright ª 2013, Cardiological Society of India. All rights reserved.Sudden cardiac death (SCD) is a major cause of mortality in
Western countries: its incidence is estimated to range be-
tween 300,000 and 400,000 cases per year in the USA and a
similar number in Europe. The definition of its incidence is
complicated by the loose definition of SCD and by the fact that,
in most instances, it is unwitnessed. In most textbooks SCD is
defined as an “unexpected death occurring within one hour
from onset of symptoms in an individual with stable clinical
conditions before the onset of the life-threatening arrhythmic
event”. It is estimated that 80% of SCD occur in individuals
with ischemic heart disease: accordingly, the prevalence of
SCD increases with age.
The term “juvenile SCD” is used to refer to SCD that occurs
in individuals under the age of 40 years: it has been suggestedaugeri Foundation, Via M
2013, Cardiological Societhat approximately 15,000 juvenile SCD/year occur in Europe
and 10,000 juvenile SCD/year in the USA. Most of the SCD in
the young occur as a consequence of inherited diseases,
mainly cardiomyopathies or channelopathies. Anatomical
abnormalities (anomalous coronary arteries), myocarditis,
ruptured aortic aneurysms are among non-genetic conditions
associated with juvenile SCD.
Prevention of SCD heavily depends on the availability of
risk stratification algorithms that allow to identify the subset
of individuals at higher risk of cardiac arrhythmias in the
larger pool of patients with common diseases such as heart
failure. A similar risk stratification process to identify subjects
with higher risk of SCD applies to patients affected by
monogenic diseases that predispose to SCD. Unfortunately,augeri, 10-27100 Pavia, Italy. Tel.: þ39 0382 592040; fax: þ39 0382
ty of India. All rights reserved.
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dispose to life-threatening arrhythmias is limited: risk in-
dicators are at most able to identify broad categories of
individuals with higher risk, but they remain far from being
able to quantify individual risk of dying suddenly.
The term personalized medicine has been recently intro-
duced to refer to the ability to integrate clinical, molecular and
environmental markers of risk of becoming sick or dying.
Although the term has been most successfully applied to
oncology, there is hope that it may be possible to identify
specific prognostic biomarkers in other fields of medicine,
including cardiology.
In this editorial, I will try to summarize how clinical ge-
netics may help in designing a personalized approach to the
prevention of SCD by integrating clinical andmolecular data. I
will approach this topic by discussing first where we stand in
the use of genetics for risk stratification and therapy selection
in monogenic diseases and I will then move to discuss the
contribution of genetics to patient profiling in acquired car-
diovascular diseases.1. Molecular genetics and prevention of SCD
in Inherited Arrhythmogenic Diseases (IADs)
IADs are considered uncommon diseases with an estimated
prevalence between 1 in 500 to 1 in 10,000, with an average
prevalence of around 1 in 2,000. IADs can be divided in two
groups: “cardiomyopathies” that are disorders presenting
abnormal structure and function of cardiac muscle and
“channelopathies” that have no structural abnormalities of
the heart, but predispose to life-threatening arrhythmias. In
these genetic diseases the prognosis is influenced by the type
of causative mutation. For example, in Long QT Syndrome
(LQTS) there are major differences in outcome among the
three most common genetic variants of the disease: LQT1
(caused by mutations in the KCNQ1 gene that encodes for a
potassium channel), LQT2 (caused by mutations in the KCNH2
gene that encodes for another potassium channel) and LQT3
(caused by mutations in the SCN5A gene encoding for the
cardiac sodium channel). In this setting patients affected with
LQT1 have the most favorable prognosis, they respond well to
medical treatmentwith beta-blockers and they do not need an
Implantable Cardioverter Defibrillator (ICD).1 Patients with
LQT2 and LQT3 have a more severe prognosis and a reduced
response to beta-blockers, thus theymay need to be protected
by an ICD. Based on these data a risk stratification scheme has
been proposed for LQTS patients, which combines clinical
parameters such as gender and the duration of QT interval as
well as molecular data, such as the “gene” in which the
causative mutation is located.1 Accordingly, LQTS patients
with a higher risk of death are patients with mutations in the
KCNH2 gene and in the SCN5A gene, who also have a QTc
duration that exceeds 500 ms.
More recently the field has advanced thanks to the evi-
dence that the location of the mutation within the coding
region of the causative gene can add information to risk
stratification schemes and the mutations located in func-
tionally relevant regions of the protein are the most delete-
rious.2 Among the IADs Long QT Syndrome is clearly thedisease that is closest to having a personalized management
and risk profiling schemes that integrate clinical characteris-
tics and the individual genetic background. It is expected that,
as our knowledge advances, it will become possible to extend
the contribution of genetics to the prediction of outcome in
other cardiomyopathies and channelopathies.2. Is susceptibility to SCD influenced by
genetic factors in the general population?
In the last few years, several clinical studies demonstrated
that having a family history of SCD is associated with a sig-
nificant increase in the individual risk of dying suddenly. The
Paris prospective study3 was one of the first observational
studies suggesting that family history of SCD on either the
paternal or thematernal side of the family is associatedwith a
relative risk of 1.89 of dying suddenly and that the presence of
family history of SCD on both sides of families is associated
with an hazard ratio of 9.4 of dying suddenly. These data were
later confirmed by Friedlander et al4 who showed that a
parental history of early-onset sudden death (age <65) is
associated with an increased risk of SCD (odds ratio ¼ 2.69),
after adjustment for parental history of myocardial infarction
and other risk factors. These data encouraged investigators to
design studies to search for common genetic variants called
single nucleotide polymorphisms (SNPs) that could predis-
pose to the risk of sudden death.3. How to search for genetic markers that
predispose to SCD?
The first method used to search for the genetic basis of SCD is
called “candidate gene approach”. This approach tests the
hypothesis that SNPs located in genes that are known to cause
SCD in patients with IADs or in genes that are known to
modify electrical parameters that predispose to SCD, e.g. the
QT interval, could predispose to SCD in the general popula-
tion. This method proved to be quite useful and allowed for
the identification of several common DNA variants linked to
increased risk of SCD.
One of the first SNP identified as an indicator of sus-
ceptibility to develop SCD was the S1102Y5 polymorphism in
the gene encoding for the cardiac sodium channel SCN5A.
This DNA variant is present in 13% of the African-ancestry
population and it was shown to significantly increase the
risk of SCD in the Afro-American population (P ¼ 0.000028).
Similarly, Albert et al6 identified SNPs in the SCN5A gene
associated with risk of SCD in Caucasian women, while in
the same study no SNPs associated with SCD risk in men
were found. In another study, Dr Albert and colleagues
analyzed a population of 516 SCD cases and 1522 matched
controls of European ancestry and investigated 147 SNPs for
association with SCD. Two SNPs located in intron 11 of the
KCNQ1 gene and in intron 1 of the SCN5A gene were
significantly associated with sudden/arrhythmic death.7
These data demonstrated that common variants in genes
that cause LQTS may also increase risk of SCD in the general
population.
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investigated to test whether they predispose to SCD are
located on genes that modulate duration of cardiac repolari-
zation, such as SNPs located at the NOS1AP locus (Nitric oxide
synthase 1 adaptor protein). Kao et al genotyped a series of
SNPs in the NOS1AP locus in 498 SCD cases and 19,295 con-
trols.8 The SNP most strongly associated with QT interval,
called rs16847548, was also associated with increased risk for
SCD in the general population. Interestingly, SNPs in NOS1AP
have also been associated with QT prolongation and cardiac
events in LQTS.94. Genome Wide Association Study (GWAS):
a powerful approach to search for SNPs linked to
SCD
The second type of studies used to investigate the genetic sub-
strate of SCD is called Genome Wide Association Studies
(GWAS). At variance with the candidate gene approach that fo-
cuses on a selected number of SNPs located on genes that
modulate electrophysiological parameters, GWAS intends to
test largepanelsof unselectedSNPs innormal individualsand in
group of patients with specific diseases, to identify which SNPs
maypredispose to theiroccurrence.Tosummarize the results of
GWAS studies that investigated the genetic predisposition to
SCD, I report the interesting results by Arking et al10 who
performedameta-analysisofGWASstudiesonpredispositionof
SCD including 3119 SCD cases and 11,146 controls.10 This
study identified a strong signal for SCD susceptibility at locus
2q24.2. In this study the strongest associationmaps to an intron
in BAZ2B gene, however, the signal also extends to theWDSUB1
andTANC1 genes. All three genes are expressed inhumanheart
and may act during cardiogenesis and modulate the develop-
ment of the autonomic nervous system.5. How do all these data come together and
what to expect for the future?
This brief overview has highlighted that in the past ten years
major advances have been made in the attempt to define the
genetic imprinting that predisposes to SCD. The rapid devel-
opment of our understanding of the genetics underlying
Mendelian arrhythmogenic syndromes has clearly paved the
way to the application of molecular genetics to investigate the
heritable component of sudden death in the general
population.
The evidence that common DNA variants located in genes
that cause Long QT Syndrome and Brugada Syndrome, namely
KCNQ1 and SCN5A, predispose to SCD the general population is
quite intriguing and certainly deservesmore investigation. The
knowledge that the duration of intervals of the electrocardio-
gram is largely determined by genetic factors is now an estab-
lished finding that has reinforced the importance of the
duration of QT interval in the general population and its asso-
ciation with SCD. The observation that polymorphisms in the
gene NOS1AP, that is the strongest modifier of QT interval
duration,arecriticallyassociatedwithaugmentedriskofSCDin
the general population represents a major finding that, ifconfirmed in prospective studies, may change our approach to
risk stratification for SCD. Finally, GWAS studies have sug-
gested that few genes that encode proteins with unknown
function but highly expressed in the heart, may also harbor
critical DNA variants that influence the probability of dying
suddenly.
The bulk of knowledge produced in this field has estab-
lished “genetics of SCD” as a novel and rapidly progressing
topic of research that is likely to redefine risk stratification
algorithms for cardiovascular diseases. As we look to the
future we have to remember that all the DNA variants iden-
tified so far do not act in isolation, but rather they are deeply
influenced by a mutual interaction and by the modulation
induced by the environment. Studies that incorporate the
cumulative effect of different SNPs, as well as the influence of
the “exposome” defined as the lifelong environmental influ-
ence that acts on the genetic substrate, have not yet been
performed and they represent the new challenge for the
future advancement of the field.Conflicts of interest
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